During the past decade, South Texas Accelerated Research Therapeutics conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 4 clinical trials were completed, i.e. on average, 6.9% percent of trials that started reached the finish line to date. In the past 5 years, 23 clinical trials started and 3 clinical trials were completed. i.e. 13% of trials that started reached the finish line.

Out of the total clinical trials conducted in "South Texas Accelerated Research Therapeutics" #1 sponsor was "Incyte Corporation" with 6 trials, followed by "Celgene" with 5 trials sponsored, "Daiichi Sankyo, Inc." with 5 trials sponsored, "Seagen Inc." with 5 trials sponsored and "Asana BioSciences" with 5 trials sponsored. Other sponsors include 74 different institutions and companies that sponsored additional 61 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "South Texas Accelerated Research Therapeutics" #1 collaborator was "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 2 trials as a collaborator, "Medpace, Inc." with 2 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator and "Arcus Biosciences, Inc." with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "South Texas Accelerated Research Therapeutics" are "Solid Tumors" (20 trials), "Breast Cancer" (9 trials), "Cancer" (9 trials), "Ovarian Cancer" (8 trials) and "Advanced Solid Tumors" (7 trials). Many other conditions were trialed in "South Texas Accelerated Research Therapeutics" in a lesser frequency.

Most popular intervention types in "South Texas Accelerated Research Therapeutics" are "Drug" (99 trials), "Biological" (8 trials), "Other" (3 trials), "Dietary Supplement" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (11 trials), "Retifanlimab" (4 trials), "Carboplatin" (3 trials), "Docetaxel" (3 trials) and "Abiraterone acetate" (2 trials). Other intervention names were less common.

The vast majority of trials in "South Texas Accelerated Research Therapeutics" are 97 trials for "All" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "South Texas Accelerated Research Therapeutics". undefined are not yet recruiting, 23 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in South Texas Accelerated Research Therapeutics, 1 suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in South Texas Accelerated Research Therapeutics, 99 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".